Oct 28, 2026 earnings call — Raised guidance and highlighted acquisitions and quality
Ensign raised 2026 earnings guidance to $7.94 to $8.02 per diluted share and lifted revenue guidance to $5.89 billion to $5.92 billion.
Revenue $1.5B (est $1.5B) · EPS $2.03 (est $1.97) · Next-quarter revenue outlook $5.9B–$5.9B
Key quotes
"According to the most recently published Centers for Medicare and Medicaid Services data, for our same store facilities, we achieved quality measure ratings that were 21% above the average of the states we operate in."
"During the quarter and since, we added 22 new operations. Including 3 real estate assets and 19 leased operations."
"Other key metrics as of September 30 include cash and cash equivalents, $337.6 million and cash flow from operations of $512.3 million."
Analyst Q&A 4
Risks entering Florida and integration
Q (Ben Hendrix · RBC): He asked what unique challenges Ensign saw in Florida during diligence across network, regulation, labor, payers, or other areas. In a follow-up he asked about hurdles to bring higher-acuity SNF volume into new Florida facilities.
A: Management said Florida has long been a target but the litigation environment was a major deterrent. They said the current rate environment is strong, labor is good, regulation is middle of the road, and a longtime leader has moved there to lead the transition. They also said existing plan relationships let them arrange LOAs and one-off deals to bring higher-acuity patients, but it will take time to prove outcomes.
"The litigation environment is really busy. and that makes it sort of a deterrent for operators to come into the state." — Barry R. Port (CEO)
Core performance and AI/documentation plans
Q (David MacDonald · Truist): He asked whether the core business and recent acquisitions (for example, Texas) are outperforming and contributing to the stronger Q4 guide. He then asked about automation/AI initiatives for clinical documentation and timing of meaningful rollout.
A: Management said many recent deals are turnaround assets and will be slower to contribute; some Texas buildings are not yet accretive but may contribute in Q4. They said the core business is expected to remain strong, noting they are stepping out of Q3 at "84% on same store and 86.0% occupancy on same store" with elevated skilled mix. On technology, they described many projects using Copilot and other tools, focusing on clinical documentation support, coding and compliance, working with their EMR provider and building internal tools.
"Acquisitions that are turnaround in nature and will be slower to contribute." — Barry R. Port (CEO)
Skilled mix strength and M&A pace
Q (Raj Kumar · Stephens): He asked what is supporting sustained high skilled mix post-COVID — demand, market share, or higher-acuity referrals. His follow-up asked about M&A pacing and whether the baseline should be above historic levels (e.g., more than ~20 facilities per year).
A: Management said the skilled mix gains are driven by consistent clinical outcomes, trust across the care continuum, and some demographic tailwinds, and that growth appears across all payers. On M&A, they said they are opportunistic, do not set fixed growth targets, leadership pipeline is a constraint (they have "55 or so AITs" in the program), and that "50 to 60 acquisitions a year is totally doable." They added deal flow is strong but they will remain selective.
"50 to 60 acquisitions a year is totally doable. If not more." — Chad A. Keetch
Deal sources and buying leased properties
Q (AJ Rice · UBS): He asked whether certain deal sources (nonprofit health systems, REITs, field-sourced deals) are becoming more plentiful and whether sources skew toward premium versus turnaround assets. In a follow-up he asked whether buying leased properties will come as a bolus or a steady stream.
A: Management said deals are coming from all sources and that they have seen more higher-quality physical-plant portfolios lately, though they still do turnarounds. For leased properties, they described buying a handful from a large public REIT after long leases ("nearly 20 years") and buying family-owned lease portfolios over time; they noted "2-thirds of our portfolio will be leased" presents ongoing opportunity and that ownership gives operational and value benefits.
"And I do not know if that is because, you know, we have done some, and so people are thinking, hey, Ensign will buy not just turnarounds with some of these nicer assets." — Chad A. Keetch